CSL, a leading global biotech company dedicated to developing innovative biotherapies for life-threatening medical conditions, is now accepting applications for their 2026 Research Acceleration Initiative. This initiative aims to fast-track the discovery of breakthrough treatments through strategic partnerships with global research organizations.

Selected applicants will receive up to $400,000 USD in funding over two years to support research projects that align with CSL’s Therapeutic Areas (including cardiovascular and renal diseases, hematology, transplant and immunology, vaccines, plasma protein research, and gene editing) and incorporate CSL’s advanced platform technologies.

Contact Anita Rao (arao@ufl.edu) to express interest and receive online application instructions. Submission deadline for the 300-word non-confidential abstract is due CSL by February 24, 2026. To learn more about the initiative, click here.

You can also learn more by attending an information webinar:
Thursday, 29 January 11:00AM EST – Click to join
Thursday, 5 February 1:00PM EST – Click to join